Kinase Inhibitor

DrugDrug NameDrug Indication
DB00317GefitinibFor the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
DB00398SorafenibSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
DB00530ErlotinibFor the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
DB00619ImatinibFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB01254DasatinibFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DB01259LapatinibIndicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB04868NilotinibFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
DB05239CobimetinibFor the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.
DB05294VandetanibVandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
DB06589PazopanibTreatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
DB06595MidostaurinInvestigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB06626AxitinibUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
DB08865CrizotinibCrizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
DB08875CabozantinibFor the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DB08877RuxolitinibTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
DB08881VemurafenibVemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
DB08896RegorafenibRegorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
DB08901PonatinibPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
DB08911TrametinibTrametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
DB08912DabrafenibDabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
DB08916AfatinibAfatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
DB09053IbrutinibIbrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenstr├Âm's Macroglobulinemia (WM). In August 2017, ibrutinib was approved for the treatment of chronic graft versus host disease patients who have failed one or more other therapies [L937].
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB09063CeritinibCeritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB09073PalbociclibPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DB09078LenvatinibLenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
DB09079NintedanibNintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DB09330OsimertinibOsimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.
DB11363AlectinibAlectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB11730RibociclibKisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
DB11828NeratinibFor use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
DB12001Abemaciclib* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
DB12267BrigatinibThe anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]
DB12483CopanlisibIndicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
DrugDrug NameTargetType
DB00317GefitinibEpidermal growth factor receptortarget
DB00317GefitinibCytochrome P450 3A4enzyme
DB00317GefitinibCytochrome P450 2D6enzyme
DB00317GefitinibMultidrug resistance protein 1transporter
DB00317GefitinibATP-binding cassette sub-family G member 2transporter
DB00317GefitinibCytochrome P450 3A5enzyme
DB00317GefitinibCytochrome P450 1A1enzyme
DB00317GefitinibCytochrome P450 2C9enzyme
DB00317GefitinibCytochrome P450 2C19enzyme
DB00317GefitinibSerum albumincarrier
DB00317GefitinibAlpha-1-acid glycoprotein 1carrier
DB00398SorafenibSerine/threonine-protein kinase B-raftarget
DB00398SorafenibReceptor-type tyrosine-protein kinase FLT3target
DB00398SorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB00398SorafenibVascular endothelial growth factor receptor 3target
DB00398SorafenibPlatelet-derived growth factor receptor betatarget
DB00398SorafenibMast/stem cell growth factor receptor Kittarget
DB00398SorafenibVascular endothelial growth factor receptor 2target
DB00398SorafenibCytochrome P450 3A4enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-9enzyme
DB00398SorafenibCytochrome P450 2B6enzyme
DB00398SorafenibCytochrome P450 2C8enzyme
DB00398SorafenibCytochrome P450 3A5enzyme
DB00398SorafenibCytochrome P450 3A7enzyme
DB00398SorafenibCytochrome P450 2C9enzyme
DB00398SorafenibMultidrug resistance-associated protein 4transporter
DB00398SorafenibMultidrug resistance protein 1transporter
DB00398SorafenibCanalicular multispecific organic anion transporter 1transporter
DB00398SorafenibATP-binding cassette sub-family G member 2transporter
DB00398SorafenibCytochrome P450 1A2enzyme
DB00398SorafenibCytochrome P450 2C19enzyme
DB00398SorafenibCytochrome P450 2D6enzyme
DB00398SorafenibUDP-glucuronosyltransferase 1-1enzyme
DB00398SorafenibRalA-binding protein 1transporter
DB00398SorafenibFibroblast growth factor receptor 1target
DB00398SorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB00398SorafenibVascular endothelial growth factor receptor 1target
DB00530ErlotinibEpidermal growth factor receptortarget
DB00530ErlotinibCytochrome P450 3A4enzyme
DB00530ErlotinibATP-binding cassette sub-family G member 2transporter
DB00530ErlotinibMultidrug resistance protein 1transporter
DB00530ErlotinibNuclear receptor subfamily 1 group I member 2target
DB00530ErlotinibCytochrome P450 3A5enzyme
DB00530ErlotinibCytochrome P450 1A1enzyme
DB00530ErlotinibCytochrome P450 1A2enzyme
DB00530ErlotinibCytochrome P450 1B1enzyme
DB00530ErlotinibCytochrome P450 2D6enzyme
DB00530ErlotinibCytochrome P450 2C8enzyme
DB00530ErlotinibUDP-glucuronosyltransferase 1-1enzyme
DB00530ErlotinibSerum albumincarrier
DB00530ErlotinibAlpha-1-acid glycoprotein 1carrier
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00877SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00877SirolimusCytochrome P450 3A4enzyme
DB00877SirolimusSerine/threonine-protein kinase mTORtarget
DB00877SirolimusFibroblast growth factor 2target
DB00877SirolimusCytochrome P450 3A5enzyme
DB00877SirolimusCytochrome P450 3A7enzyme
DB00877SirolimusMultidrug resistance protein 1transporter
DB00877SirolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusMultidrug and toxin extrusion protein 1transporter
DB01254DasatinibTyrosine-protein kinase ABL1target
DB01254DasatinibAbelson tyrosine-protein kinase 2target
DB01254DasatinibProto-oncogene tyrosine-protein kinase Srctarget
DB01254DasatinibTyrosine-protein kinase Fyntarget
DB01254DasatinibTyrosine-protein kinase Lcktarget
DB01254DasatinibTyrosine-protein kinase Yestarget
DB01254DasatinibMast/stem cell growth factor receptor Kittarget
DB01254DasatinibPlatelet-derived growth factor receptor betatarget
DB01254DasatinibEphrin type-A receptor 2target
DB01254DasatinibSignal transducer and activator of transcription 5Btarget
DB01254DasatinibCytochrome P450 3A4enzyme
DB01254DasatinibMultidrug resistance protein 1transporter
DB01254DasatinibATP-binding cassette sub-family G member 2transporter
DB01254DasatinibCytochrome P450 1A1enzyme
DB01254DasatinibCytochrome P450 1A2enzyme
DB01254DasatinibCytochrome P450 1B1enzyme
DB01254DasatinibCytochrome P450 3A5enzyme
DB01254DasatinibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB01254DasatinibTyrosine-protein kinase BTKtarget
DB01254DasatinibNuclear receptor subfamily 4 group A member 3target
DB01254DasatinibBreakpoint cluster region proteintarget
DB01254DasatinibTyrosine-protein kinase CSKtarget
DB01254DasatinibEphrin type-A receptor 5target
DB01254DasatinibEphrin type-B receptor 4target
DB01254DasatinibTyrosine-protein kinase Fgrtarget
DB01254DasatinibTyrosine-protein kinase FRKtarget
DB01254DasatinibHeat shock cognate 71 kDa proteintarget
DB01254DasatinibTyrosine-protein kinase Lyntarget
DB01254DasatinibMitogen-activated protein kinase kinase kinase MLTtarget
DB01254DasatinibMitogen-activated protein kinase 14target
DB01254DasatinibAmidophosphoribosyltransferasetarget
DB01259LapatinibEpidermal growth factor receptortarget
DB01259LapatinibReceptor tyrosine-protein kinase erbB-2target
DB01259LapatinibCytochrome P450 3A4enzyme
DB01259LapatinibCytochrome P450 2C8enzyme
DB01259LapatinibMultidrug resistance protein 1transporter
DB01259LapatinibAntigen peptide transporter 1transporter
DB01259LapatinibCytochrome P450 3A5enzyme
DB01259LapatinibCytochrome P450 2C19enzyme
DB01268SunitinibPlatelet-derived growth factor receptor betatarget
DB01268SunitinibVascular endothelial growth factor receptor 1target
DB01268SunitinibVascular endothelial growth factor receptor 2target
DB01268SunitinibVascular endothelial growth factor receptor 3target
DB01268SunitinibMast/stem cell growth factor receptor Kittarget
DB01268SunitinibReceptor-type tyrosine-protein kinase FLT3target
DB01268SunitinibMacrophage colony-stimulating factor 1 receptortarget
DB01268SunitinibPlatelet-derived growth factor receptor alphatarget
DB01268SunitinibCytochrome P450 3A4enzyme
DB01268SunitinibCytochrome P450 3A5enzyme
DB01268SunitinibCytochrome P450 3A7enzyme
DB01268SunitinibMultidrug resistance-associated protein 4transporter
DB01268SunitinibMultidrug resistance protein 1transporter
DB01268SunitinibCanalicular multispecific organic anion transporter 1transporter
DB01268SunitinibATP-binding cassette sub-family G member 2transporter
DB01590EverolimusSerine/threonine-protein kinase mTORtarget
DB01590EverolimusCytochrome P450 3A4enzyme
DB04868NilotinibTyrosine-protein kinase ABL1target
DB04868NilotinibMast/stem cell growth factor receptor Kittarget
DB04868NilotinibCytochrome P450 2D6enzyme
DB04868NilotinibCytochrome P450 2C8enzyme
DB04868NilotinibCytochrome P450 2C9enzyme
DB04868NilotinibCytochrome P450 3A4enzyme
DB04868NilotinibMultidrug resistance protein 1transporter
DB04868NilotinibATP-binding cassette sub-family G member 2transporter
DB04868NilotinibUDP-glucuronosyltransferase 1-1transporter
DB04868NilotinibCytochrome P450 2B6enzyme
DB05239CobimetinibDual specificity mitogen-activated protein kinase kinase 1target
DB05239CobimetinibCYP3Aenzyme
DB05239CobimetinibMultidrug resistance protein 1enzyme
DB05239CobimetinibSolute carrier organic anion transporter family member 1B1transporter
DB05239CobimetinibSolute carrier organic anion transporter family member 1B3transporter
DB05239CobimetinibATP-binding cassette sub-family G member 2transporter
DB05294VandetanibVascular endothelial growth factor Atarget
DB05294VandetanibEpidermal growth factor receptortarget
DB05294VandetanibMultidrug resistance-associated protein 1transporter
DB05294VandetanibATP-binding cassette sub-family G member 2transporter
DB05294VandetanibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB05294VandetanibDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB05294VandetanibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB05294VandetanibProtein-tyrosine kinase 6target
DB05294VandetanibAngiopoietin-1 receptortarget
DB05294VandetanibAlpha-1-acid glycoprotein 1carrier
DB05294VandetanibSerum albumincarrier
DB05294VandetanibCytochrome P450 3A4enzyme
DB06589PazopanibVascular endothelial growth factor receptor 1target
DB06589PazopanibVascular endothelial growth factor receptor 2target
DB06589PazopanibVascular endothelial growth factor receptor 3target
DB06589PazopanibPlatelet-derived growth factor receptor alphatarget
DB06589PazopanibPlatelet-derived growth factor receptor betatarget
DB06589PazopanibMast/stem cell growth factor receptor Kittarget
DB06589PazopanibCytochrome P450 3A4enzyme
DB06589PazopanibCytochrome P450 2D6enzyme
DB06589PazopanibCytochrome P450 2C8enzyme
DB06589PazopanibCytochrome P450 1A2enzyme
DB06589PazopanibMultidrug resistance protein 1transporter
DB06589PazopanibATP-binding cassette sub-family G member 2transporter
DB06589PazopanibSolute carrier organic anion transporter family member 1B1transporter
DB06589PazopanibUDP-glucuronosyltransferase 1-1transporter
DB06589PazopanibFibroblast growth factor receptor 3target
DB06589PazopanibTyrosine-protein kinase ITK/TSKtarget
DB06589PazopanibFibroblast growth factor 1target
DB06589PazopanibSH2B adapter protein 3target
DB06595MidostaurinProtein kinase C alpha typetarget
DB06595MidostaurinVascular endothelial growth factor receptor 2target
DB06595MidostaurinMast/stem cell growth factor receptor Kittarget
DB06595MidostaurinPlatelet-derived growth factor receptor alphatarget
DB06595MidostaurinPlatelet-derived growth factor receptor betatarget
DB06595MidostaurinReceptor-type tyrosine-protein kinase FLT3target
DB06595MidostaurinCytochrome p450 3A subfamilyenzyme
DB06595MidostaurinCytochrome P450 1A2enzyme
DB06595MidostaurinCytochrome P450 2B6enzyme
DB06595MidostaurinCytochrome P450 2C8enzyme
DB06595MidostaurinCytochrome P450 2C9enzyme
DB06595MidostaurinCytochrome P450 2C19enzyme
DB06595MidostaurinCytochrome P450 2D6enzyme
DB06595MidostaurinCytochrome P450 2E1enzyme
DB06595MidostaurinCytochrome P450 3A4enzyme
DB06595MidostaurinCytochrome P450 3A5enzyme
DB06595MidostaurinCytochrome P450 3A7enzyme
DB06595MidostaurinCytochrome P450 3A43enzyme
DB06616BosutinibBreakpoint cluster region proteintarget
DB06616BosutinibTyrosine-protein kinase ABL1target
DB06616BosutinibTyrosine-protein kinase Lyntarget
DB06616BosutinibTyrosine-protein kinase HCKtarget
DB06616BosutinibProto-oncogene tyrosine-protein kinase Srctarget
DB06616BosutinibMultidrug resistance protein 1transporter
DB06616BosutinibCytochrome P450 3A4enzyme
DB06616BosutinibCyclin-dependent kinase 2target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 1target
DB06616BosutinibDual specificity mitogen-activated protein kinase kinase 2target
DB06616BosutinibMitogen-activated protein kinase kinase kinase 2target
DB06616BosutinibCalcium/calmodulin-dependent protein kinase type II subunit gammatarget
DB06626AxitinibVascular endothelial growth factor receptor 1target
DB06626AxitinibVascular endothelial growth factor receptor 2target
DB06626AxitinibVascular endothelial growth factor receptor 3target
DB06626AxitinibCytochrome P450 3A4enzyme
DB06626AxitinibCytochrome P450 3A5enzyme
DB06626AxitinibCytochrome P450 1A2enzyme
DB06626AxitinibCytochrome P450 2C19enzyme
DB06626AxitinibUDP-glucuronosyltransferase 1-1enzyme
DB06626AxitinibMultidrug resistance protein 1transporter
DB06626AxitinibSolute carrier organic anion transporter family member 1B1transporter
DB08865CrizotinibCytochrome P450 3A4enzyme
DB08865CrizotinibCytochrome P450 3A5enzyme
DB08865CrizotinibMultidrug resistance protein 1transporter
DB08865CrizotinibALK tyrosine kinase receptortarget
DB08865CrizotinibHepatocyte growth factor receptortarget
DB08865CrizotinibCytochrome P450 2B6enzyme
DB08875CabozantinibCytochrome P450 3A4enzyme
DB08875CabozantinibCytochrome P450 2C9enzyme
DB08875CabozantinibHepatocyte growth factor receptortarget
DB08875CabozantinibVascular endothelial growth factor receptor 2target
DB08875CabozantinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08877RuxolitinibTyrosine-protein kinase JAK1target
DB08877RuxolitinibTyrosine-protein kinase JAK2target
DB08877RuxolitinibCytochrome P450 3A4enzyme
DB08881VemurafenibSerum albumincarrier
DB08881VemurafenibAlpha-1-acid glycoprotein 1carrier
DB08881VemurafenibCytochrome P450 1A2enzyme
DB08881VemurafenibCytochrome P450 2D6enzyme
DB08881VemurafenibCytochrome P450 3A4enzyme
DB08881VemurafenibSerine/threonine-protein kinase B-raftarget
DB08881VemurafenibMultidrug resistance-associated protein 1transporter
DB08881VemurafenibATP-binding cassette sub-family G member 2transporter
DB08896RegorafenibCytochrome P450 3A4enzyme
DB08896RegorafenibUDP-glucuronosyltransferase 1-9enzyme
DB08896RegorafenibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08896RegorafenibVascular endothelial growth factor receptor 1target
DB08896RegorafenibVascular endothelial growth factor receptor 2target
DB08896RegorafenibVascular endothelial growth factor receptor 3target
DB08896RegorafenibMast/stem cell growth factor receptor Kittarget
DB08896RegorafenibPlatelet-derived growth factor receptor alphatarget
DB08896RegorafenibPlatelet-derived growth factor receptor betatarget
DB08896RegorafenibFibroblast growth factor receptor 1target
DB08896RegorafenibFibroblast growth factor receptor 2target
DB08896RegorafenibAngiopoietin-1 receptortarget
DB08896RegorafenibDiscoidin domain-containing receptor 2target
DB08896RegorafenibHigh affinity nerve growth factor receptortarget
DB08896RegorafenibEphrin type-A receptor 2target
DB08896RegorafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08896RegorafenibSerine/threonine-protein kinase B-raftarget
DB08896RegorafenibCytochrome P450 2C8enzyme
DB08896RegorafenibCytochrome P450 2C9enzyme
DB08896RegorafenibCytochrome P450 2B6enzyme
DB08896RegorafenibCytochrome P450 2C19enzyme
DB08896RegorafenibMitogen-activated protein kinase 11target
DB08896RegorafenibTyrosine-protein kinase FRKtarget
DB08896RegorafenibTyrosine-protein kinase ABL1target
DB08896RegorafenibMultidrug resistance protein 1transporter
DB08896RegorafenibATP-binding cassette sub-family G member 2transporter
DB08896RegorafenibUDP-glucuronosyltransferase 1-1enzyme
DB08901PonatinibTyrosine-protein kinase ABL1target
DB08901PonatinibBreakpoint cluster region proteintarget
DB08901PonatinibMast/stem cell growth factor receptor Kittarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08901PonatinibAngiopoietin-1 receptortarget
DB08901PonatinibReceptor-type tyrosine-protein kinase FLT3target
DB08901PonatinibCytochrome P450 3A4enzyme
DB08901PonatinibCytochrome P450 2C8enzyme
DB08901PonatinibCytochrome P450 2D6enzyme
DB08901PonatinibCytochrome P450 3A5enzyme
DB08901PonatinibMultidrug resistance protein 1transporter
DB08901PonatinibATP-binding cassette sub-family G member 2transporter
DB08901PonatinibFibroblast growth factor receptor 1target
DB08901PonatinibFibroblast growth factor receptor 2target
DB08901PonatinibFibroblast growth factor receptor 3target
DB08901PonatinibFibroblast growth factor receptor 4target
DB08901PonatinibTyrosine-protein kinase Lcktarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase Srctarget
DB08901PonatinibTyrosine-protein kinase Lyntarget
DB08901PonatinibVascular endothelial growth factor receptor 2target
DB08901PonatinibPlatelet-derived growth factor receptor alphatarget
DB08901PonatinibBile salt export pumptransporter
DB08911TrametinibCytochrome P450 2C8enzyme
DB08911TrametinibCytochrome P450 3A4enzyme
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 1target
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 2target
DB08912DabrafenibCytochrome P450 3A4enzyme
DB08912DabrafenibCytochrome P450 2C8enzyme
DB08912DabrafenibMultidrug resistance protein 1transporter
DB08912DabrafenibATP-binding cassette sub-family G member 2transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B1transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B3transporter
DB08912DabrafenibSolute carrier family 22 member 6transporter
DB08912DabrafenibSolute carrier family 22 member 8transporter
DB08912DabrafenibSerine/threonine-protein kinase B-raftarget
DB08912DabrafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08912DabrafenibSerine/threonine-protein kinase SIK1target
DB08912DabrafenibSerine/threonine-protein kinase Nek11target
DB08912DabrafenibLIM domain kinase 1target
DB08916AfatinibEpidermal growth factor receptortarget
DB08916AfatinibReceptor tyrosine-protein kinase erbB-2target
DB08916AfatinibReceptor tyrosine-protein kinase erbB-4target
DB08916AfatinibMultidrug resistance protein 1transporter
DB08916AfatinibATP-binding cassette sub-family G member 2transporter
DB09053IbrutinibTyrosine-protein kinase BTKtarget
DB09053IbrutinibCytochrome P450 3A4enzyme
DB09053IbrutinibCytochrome P450 3A5enzyme
DB09053IbrutinibCytochrome P450 2D6enzyme
DB09054IdelalisibPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110╬┤)target
DB09054IdelalisibATP-binding cassette sub-family G member 2transporter
DB09054IdelalisibMultidrug resistance protein 1transporter
DB09054IdelalisibAldehyde oxidaseenzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A4enzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A1enzyme
DB09054IdelalisibCytochrome P450 2C8enzyme
DB09054IdelalisibCytochrome P450 2C19enzyme
DB09054IdelalisibCytochrome P450 2B6enzyme
DB09054IdelalisibCytochrome P450 3A4enzyme
DB09054IdelalisibSolute carrier organic anion transporter family member 1B1transporter
DB09054IdelalisibSolute carrier organic anion transporter family member 1B3transporter
DB09054IdelalisibCytochrome P450 3A5enzyme
DB09054IdelalisibCytochrome P450 3A43enzyme
DB09054IdelalisibCytochrome P450 3A7enzyme
DB09063CeritinibALK tyrosine kinase receptortarget
DB09063CeritinibMultidrug resistance protein 1transporter
DB09063CeritinibCytochrome P450 3A4enzyme
DB09063CeritinibCytochrome P450 2C9enzyme
DB09073PalbociclibCyclin-dependent kinase 4target
DB09073PalbociclibCyclin-dependent kinase 6target
DB09073PalbociclibCytochrome P450 3A4enzyme
DB09073PalbociclibSulfotransferase 2A1enzyme
DB09078LenvatinibVascular endothelial growth factor receptor 1target
DB09078LenvatinibVascular endothelial growth factor receptor 2target
DB09078LenvatinibVascular endothelial growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 1target
DB09078LenvatinibFibroblast growth factor receptor 2target
DB09078LenvatinibFibroblast growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 4target
DB09078LenvatinibPlatelet derived growth factor receptor alphatarget
DB09078LenvatinibRET target
DB09078LenvatinibMast/stem cell growth factor receptor Kittarget
DB09078LenvatinibMultidrug resistance protein 1transporter
DB09078LenvatinibATP-binding cassette sub-family G member 2transporter
DB09078LenvatinibCytochrome P450 3A4enzyme
DB09078LenvatinibAldehyde oxidaseenzyme
DB09079NintedanibVascular endothelial growth factor receptor 1target
DB09079NintedanibVascular endothelial growth factor receptor 2target
DB09079NintedanibVascular endothelial growth factor receptor 3target
DB09079NintedanibPlatelet derived growth factor receptor alphatarget
DB09079NintedanibPlatelet derived growth factor receptor betatarget
DB09079NintedanibFibroblast growth factor receptor 1target
DB09079NintedanibFibroblast growth factor receptor 2target
DB09079NintedanibFibroblast growth factor receptor 3target
DB09079NintedanibReceptor-type tyrosine-protein kinase FLT3target
DB09079NintedanibTyrosine-protein kinase Lcktarget
DB09079NintedanibTyrosine-protein kinase Lyntarget
DB09079NintedanibProto-oncogene tyrosine-protein kinase Srctarget
DB09079NintedanibMultidrug resistance protein 1transporter
DB09330OsimertinibEpidermal growth factor receptortarget
DB09330OsimertinibMultidrug resistance protein 1transporter
DB09330OsimertinibATP-binding cassette sub-family G member 2transporter
DB09330OsimertinibCytochrome P450 3A4enzyme
DB09330OsimertinibCytochrome P450 1A2enzyme
DB11363AlectinibALK tyrosine kinase receptortarget
DB11363AlectinibATP-binding cassette sub-family G member 2transporter
DB11363AlectinibMultidrug resistance protein 1carrier
DB11730RibociclibCyclin-dependent kinase 4target
DB11730RibociclibCyclin-dependent kinase 6target
DB11828NeratinibCytochrome P450 3A4enzyme
DB11828NeratinibDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB11828NeratinibATP-binding cassette sub-family B member 5transporter
DB11828NeratinibEpidermal growth factor receptortarget
DB11828NeratinibSerum albumincarrier
DB11828Neratinibalpha1-acid glycoproteincarrier
DB12001AbemaciclibMultidrug and toxin extrusion protein 1transporter
DB12001AbemaciclibMultidrug and toxin extrusion protein 2transporter
DB12001AbemaciclibCyclin-dependent kinase 4target
DB12001AbemaciclibCyclin-dependent kinase 6target
DB12001AbemaciclibSerum albumincarrier
DB12001Abemaciclibalpha1-acid glycoproteincarrier
DB12001AbemaciclibCytochrome P450 3A4enzyme
DB12001AbemaciclibOrnithine carbamoyltransferase, mitochondrialtransporter
DB12001AbemaciclibMultidrug resistance protein 1transporter
DB12001AbemaciclibATP-binding cassette sub-family G member 2transporter
DB12267BrigatinibALK tyrosine kinase receptortarget
DB12267BrigatinibEpidermal growth factor receptortarget
DB12267BrigatinibTyrosine-protein kinase ABL1target
DB12267BrigatinibInsulin-like growth factor 1 receptortarget
DB12267BrigatinibReceptor-type tyrosine-protein kinase FLT3target
DB12267BrigatinibCytochrome P450 2C8enzyme
DB12267BrigatinibCytochrome P450 3A4enzyme
DB12267BrigatinibInsulin receptortarget
DB12267BrigatinibHepatocyte growth factor receptortarget
DB12267BrigatinibReceptor tyrosine-protein kinase erbB-4target
DB12267BrigatinibReceptor tyrosine-protein kinase erbB-2target
DB12267BrigatinibATP-binding cassette sub-family B member 5transporter
DB12267BrigatinibATP-binding cassette sub-family G member 2transporter
DB12267BrigatinibSolute carrier family 22 member 1transporter
DB12267BrigatinibMultidrug and toxin extrusion protein 1transporter
DB12267BrigatinibMultidrug and toxin extrusion protein 2transporter
DB12483CopanlisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB12483CopanlisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
DB12483CopanlisibCytochrome P450 3A4enzyme
DB12483CopanlisibCytochrome P450 3A5enzyme
DB12483CopanlisibCytochrome P450 3A7enzyme
DB12483CopanlisibCytochrome P450 3A43enzyme
DB12483CopanlisibMultidrug resistance protein 1transporter
DB12483CopanlisibATP-binding cassette sub-family G member 2transporter
DB12483CopanlisibMultidrug and toxin extrusion protein 2transporter
DB12483CopanlisibSerum albumincarrier